» Articles » PMID: 34842121

Common Musculoskeletal Disorders in Chronic Liver Disease Patients

Overview
Date 2021 Nov 29
PMID 34842121
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Chronic liver disease (CLD) is the commonest ailment affecting the hepatobiliary system. Six significant pathologies related to CLD include hepatic osteodystrophy (HO), increased infection susceptibility, sarcopenia, osteonecrosis of the femoral head (OFH), increased risk of periprosthetic complications and fracture. Hepatic osteodystrophy, which comprises osteopenia, osteoporosis, and osteomalacia, refers to alterations in bone mineral metabolism found in patients with CLD. The HO prevalence ranges from 13 to 95%. Low complement levels, poor opsonization capacity, portosystemic shunting, decreased albumin levels, and impaired reticuloendothelial system make the cirrhotic patients more susceptible to developing infectious diseases. Septic arthritis, osteomyelitis, prosthetic joint infection, and cellulitis were common types of CLD-associated infectious conditions. The incidence of septic arthritis is 1.5 to 2-fold higher in patients with cirrhosis. Sarcopenia, also known as muscle wasting, is one of the frequently overlooked manifestations of CLD. Sarcopenia has been shown to be independent predictor of longer mechanical ventilation, hospital stay, and 12-month mortality of post-transplantation. Alcohol and steroid abuse commonly associated with CLD are the two most important contributory factors for non-traumatic osteonecrosis. However, many studies have identified cirrhosis alone to be an independent cause of atraumatic osteonecrosis. The risk of developing OFH in cirrhosis patients increases by 2.4 folds and the need for total hip arthroplasty increases by 10 folds. Liver disease has been associated with worse outcomes and higher costs after arthroplasty. Cirrhosis is a risk factor for arthroplasty complications and is associated with a prolonged hospital stay, higher costs, readmission rates, and increased mortality after arthroplasty. Greater physician awareness of risk factors associated with musculoskeletal complications of CLD patients would yield earlier interventions, lower healthcare costs, and better overall clinical outcomes for this group of patients.

Citing Articles

Prevalence of Osteosarcopenia and Frailty in Patients with Chronic Liver Disease.

Nazir S, Abbas Z, Amjad S, Altaf A, Qadeer M, Maqbool S Euroasian J Hepatogastroenterol. 2025; 14(2):156-159.

PMID: 39802856 PMC: 11714115. DOI: 10.5005/jp-journals-10018-1442.


Comparison of the prophylactic use of ibandronate and its use in early-stage osteonecrosis in rats with steroid-induced osteonecrosis of the femoral head.

Caglar S, Dasci M, Acar A, Caglar A, Dincel Y, Cataltepe A Jt Dis Relat Surg. 2023; 34(3):640-650.

PMID: 37750269 PMC: 10546859. DOI: 10.52312/jdrs.2023.1096.


The painful joint after COVID-19 treatment: A study on joint osteonecrosis following COVID-19-related corticosteroid use.

Veizi E, Erdogan Y, Sezgin B, Karaman Y, Kilicarslan K, Firat A Jt Dis Relat Surg. 2023; 34(1):75-83.

PMID: 36700267 PMC: 9903115. DOI: 10.52312/jdrs.2023.895.


The effects of thymoquinone on steroid-induced femoral head osteonecrosis: An experimental study in rats.

Dasci M, Sarac E, Gok Yurttas A, Atci T, Uslu M, Acar A Jt Dis Relat Surg. 2022; 33(3):553-566.

PMID: 36345183 PMC: 9647667. DOI: 10.52312/jdrs.2022.752.


Hepatomusculoskeletal disorders: Coining a new term might improve the management of the musculoskeletal manifestations of chronic liver disease.

Tsagkaris C, Papadakos S, Moysidis D, Papazoglou A, Koutsogianni A, Papadakis M World J Gastrointest Pathophysiol. 2022; 13(4):124-127.

PMID: 36161230 PMC: 9350596. DOI: 10.4291/wjgp.v13.i4.124.


References
1.
Caglar O, Tokgozoglu M, Akgun R, Atilla B . Low-dose vancomycin-loaded cement spacer for two-stage revision of infected total hip arthroplasty. Jt Dis Relat Surg. 2020; 31(3):449-455. PMC: 7607947. DOI: 10.5606/ehc.2020.76108. View

2.
Neff G, Duncan C, Schiff E . The current economic burden of cirrhosis. Gastroenterol Hepatol (N Y). 2012; 7(10):661-71. PMC: 3265008. View

3.
Chang C, Chang C, Wang Y, Hu C, Chang Y, Hsieh P . Increased incidence, morbidity, and mortality in cirrhotic patients with hip fractures: A nationwide population-based study. J Orthop Surg (Hong Kong). 2020; 28(3):2309499020918032. DOI: 10.1177/2309499020918032. View

4.
Hajiabbasi A, Shafaghi A, Fayazi H, Shenavar Masooleh I, Hedayati Emami M, Ghavidel Parsa P . The factors affecting bone density in cirrhosis. Hepat Mon. 2015; 15(4):e26871. PMC: 4428083. DOI: 10.5812/hepatmon.15(4)2015.26871. View

5.
Mohan P, Ramu B, Bhaskar E, Venkataraman J . Prevalence and risk factors for bacterial skin infection and mortality in cirrhosis. Ann Hepatol. 2011; 10(1):15-20. View